Clinical Trial Update: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS [Phase 4]

View source ↗

Summary

Novartis' Phase 4 trial evaluating an individualized patient support program for treatment satisfaction in fingolimod-treated Relapsing-remitting multiple scler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: WITHDRAWN